CA2654909A1 - Formulations d'inhibiteurs de kinase nanoparticulaires - Google Patents
Formulations d'inhibiteurs de kinase nanoparticulaires Download PDFInfo
- Publication number
- CA2654909A1 CA2654909A1 CA002654909A CA2654909A CA2654909A1 CA 2654909 A1 CA2654909 A1 CA 2654909A1 CA 002654909 A CA002654909 A CA 002654909A CA 2654909 A CA2654909 A CA 2654909A CA 2654909 A1 CA2654909 A1 CA 2654909A1
- Authority
- CA
- Canada
- Prior art keywords
- less
- composition
- nanoparticulate
- ammonium chloride
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81296006P | 2006-06-13 | 2006-06-13 | |
US60/812,960 | 2006-06-13 | ||
PCT/US2007/071011 WO2007146943A2 (fr) | 2006-06-13 | 2007-06-12 | Formulations d'inhibiteurs de kinase nanoparticulaires |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2654909A1 true CA2654909A1 (fr) | 2007-12-21 |
Family
ID=38832788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002654909A Abandoned CA2654909A1 (fr) | 2006-06-13 | 2007-06-12 | Formulations d'inhibiteurs de kinase nanoparticulaires |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2043606A2 (fr) |
JP (1) | JP2009540010A (fr) |
KR (1) | KR20090018864A (fr) |
CN (1) | CN101500540A (fr) |
AU (1) | AU2007257667A1 (fr) |
CA (1) | CA2654909A1 (fr) |
TW (1) | TW200816987A (fr) |
WO (1) | WO2007146943A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8685458B2 (en) | 2009-03-05 | 2014-04-01 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
US9060938B2 (en) | 2011-05-10 | 2015-06-23 | Bend Research, Inc. | Pharmaceutical compositions of active agents and cationic dextran polymer derivatives |
WO2013105895A1 (fr) | 2012-01-13 | 2013-07-18 | Xspray Microparticles Ab | Composition pharmaceutique contenant des nanoparticules hybrides amorphes stables d'au moins un inhibiteur de la protéine kinase et d'au moins un constituant polymère stabilisant et matriciel |
MX371349B (es) * | 2012-01-13 | 2020-01-27 | Xspray Microparticles Ab | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. |
TWI535784B (zh) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | 剪切增稠配方、及包含其之複合材料 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0110087A (pt) * | 2000-04-13 | 2004-02-17 | Hsc Res Dev Lp | Compostos para modular proliferação celular |
AU2003230692A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Ltd. | Nanoparticulate compositions of map kinase inhibitors |
-
2007
- 2007-06-12 AU AU2007257667A patent/AU2007257667A1/en not_active Abandoned
- 2007-06-12 CN CNA2007800298841A patent/CN101500540A/zh active Pending
- 2007-06-12 KR KR1020097000297A patent/KR20090018864A/ko not_active Application Discontinuation
- 2007-06-12 WO PCT/US2007/071011 patent/WO2007146943A2/fr active Application Filing
- 2007-06-12 EP EP07798449A patent/EP2043606A2/fr not_active Withdrawn
- 2007-06-12 CA CA002654909A patent/CA2654909A1/fr not_active Abandoned
- 2007-06-12 JP JP2009515607A patent/JP2009540010A/ja active Pending
- 2007-06-13 TW TW096121317A patent/TW200816987A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007146943A3 (fr) | 2008-05-29 |
CN101500540A (zh) | 2009-08-05 |
TW200816987A (en) | 2008-04-16 |
KR20090018864A (ko) | 2009-02-23 |
AU2007257667A1 (en) | 2007-12-21 |
WO2007146943A2 (fr) | 2007-12-21 |
JP2009540010A (ja) | 2009-11-19 |
EP2043606A2 (fr) | 2009-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006309295B2 (en) | Nanoparticulate acetaminophen formulations | |
EP1895984B1 (fr) | Formulations d'imatinib mesylate nanoparticulaires | |
US20080213374A1 (en) | Nanoparticulate sorafenib formulations | |
AU2010254180B2 (en) | Reduction of flake-like aggregation in nanoparticulate active agent compositions | |
US20070148100A1 (en) | Nanoparticulate aripiprazole formulations | |
US20070003628A1 (en) | Nanoparticulate clopidogrel formulations | |
KR20090015994A (ko) | 나노입자형 포사코나졸 제제 | |
WO2007100466A2 (fr) | Formules de carvedilol nanoparticulé | |
EP1898882B1 (fr) | Formulations d'ebastine nanoparticulaire | |
US20070042049A1 (en) | Nanoparticulate benidipine compositions | |
US20100221327A1 (en) | Nanoparticulate azelnidipine formulations | |
CA2654909A1 (fr) | Formulations d'inhibiteurs de kinase nanoparticulaires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20130612 |